EMPRISE aims to assess the effectiveness and safety of empagliflozin in patients with type 2 diabetes (T2D) in routine care. Within EMPRISE, we investigated two diabetic retinopathy (DR) outcomes among adults with T2D initiating empagliflozin or DPP4 inhibitors (DPP4i) in 2 separate cohorts. Using data from Medicare-fee-for-service and 2 U.S. commercial claims databases (2014-2019), we compared the risk of non-proliferative DR (NPDR) onset (cohort 1) and the risk of DR progression (cohort 2). To evaluate the onset of NPDR, we identified 34,262 1:1 propensity-score matched (PSM) patient pairs without history of any DR (Table). To evaluate DR progression (see Table for definition), we identified 7,839 1:1 PSM patient pairs with history of NPDR and without diagnosis or treatment for advanced DR prior to cohort entry. We estimated pooled HR and RD/1,000 PY with 95% CI adjusting for 143 baseline covariates. Compared to DPP4i, a similar risk of NPDR onset was observed with empagliflozin initiation [HR: 1.05 (0.95, 1.16); RD: 1.52 (-1.61, 4.65)] and a decreased risk of DR progression [HR: 0.77 (0.62, 0.95); RD: -9.49 (-16.90, -2.08)], over a mean follow-up of ~8 months on treatment. In routine care in a broad population of patients with T2D empagliflozin was associated with a lower risk of DR progression in line with direction and magnitude of a similarly defined DR outcome in the EMPA-REG OUTCOME trial.

Disclosure

H.Tesfaye: None. P.T.Htoo: Employee; Johnson & Johnson. J.M.Paik: None. H.Zakoul: None. N.Schmedt: Employee; Boehringer Ingelheim International GmbH. A.Deruaz-luyet: Employee; Boehringer Ingelheim International GmbH. L.Koeneman: Employee; Eli Lilly and Company, Stock/Shareholder; Eli Lilly and Company. D.J.Wexler: Other Relationship; Novo Nordisk A/S. E.Patorno: Research Support; Boehringer Ingelheim Inc., National Institutes of Health, Patient-Centered Outcomes Research Institute, US Food and Drug Administration.

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.